Modelling human cytochromes P450 involved in drug metabolism from the CYP2C5 crystallographic template
- PMID: 12237218
- DOI: 10.1016/s0162-0134(02)00429-4
Modelling human cytochromes P450 involved in drug metabolism from the CYP2C5 crystallographic template
Abstract
A historical background to homology modelling of human P450s involved in drug metabolism is outlined, showing that the progress in crystallographic studies of bacterial forms of enzyme and, latterly, determination of a mammalian P450 crystal structure, has enabled the production of increasingly satisfactory models of human P450 enzymes. The methodology for the generation of P450 models by homology with crystallographic template structures is summarized, and recent results of CYP2C5-constructed models of P450s are described. These indicate that selective substrates are able to fit within the putative active sites of each enzyme, where key contacts with complementary amino acid residues are largely consistent with the results of site-directed mutagenesis experiments and metabolic studies. Consequently, the CYP2C5 crystal structure can be regarded at the current paradigm for homology modelling of the drug metabolizing P450s, especially those from the CYP2 family.
Similar articles
-
Homology modelling of CYP3A4 from the CYP2C5 crystallographic template: analysis of typical CYP3A4 substrate interactions.Xenobiotica. 2004 Jun;34(6):549-69. doi: 10.1080/00498250410001691325. Xenobiotica. 2004. PMID: 15277015
-
Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure.Xenobiotica. 2002 Apr;32(4):305-23. doi: 10.1080/00498250110112015. Xenobiotica. 2002. PMID: 12028664
-
Homology modelling of CYP2A6 based on the CYP2C5 crystallographic template: enzyme-substrate interactions and QSARs for binding affinity and inhibition.Toxicol In Vitro. 2003 Apr;17(2):179-90. doi: 10.1016/s0887-2333(02)00132-7. Toxicol In Vitro. 2003. PMID: 12650672
-
Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity.Xenobiotica. 2009 Aug;39(8):625-35. doi: 10.1080/00498250903000255. Xenobiotica. 2009. PMID: 19514836 Review.
-
Progress in cytochrome P450 active site modeling.Arch Biochem Biophys. 2005 Jan 15;433(2):361-8. doi: 10.1016/j.abb.2004.08.026. Arch Biochem Biophys. 2005. PMID: 15581592 Review.
Cited by
-
Structure-Based Drug Design for Cytochrome P450 Family 1 Inhibitors.Bioinorg Chem Appl. 2018 Jul 25;2018:3924608. doi: 10.1155/2018/3924608. eCollection 2018. Bioinorg Chem Appl. 2018. PMID: 30147715 Free PMC article. Review.
-
Kinetic and molecular analysis of 5-epiaristolochene 1,3-dihydroxylase, a cytochrome P450 enzyme catalyzing successive hydroxylations of sesquiterpenes.J Biol Chem. 2005 Feb 4;280(5):3686-96. doi: 10.1074/jbc.M411870200. Epub 2004 Nov 2. J Biol Chem. 2005. PMID: 15522862 Free PMC article.
-
Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme.Arch Biochem Biophys. 2006 Nov 1;455(1):61-7. doi: 10.1016/j.abb.2006.08.024. Epub 2006 Sep 25. Arch Biochem Biophys. 2006. PMID: 17027909 Free PMC article.
-
Quantitative structure-activity relationships (QSARs) within the cytochrome P450 system: QSARs describing substrate binding, inhibition and induction of P450s.Inflammopharmacology. 2003;11(1):43-73. doi: 10.1163/156856003321547112. Inflammopharmacology. 2003. PMID: 15035734
-
Studies of binding modes of (S)-mephenytoin to wild types and mutants of cytochrome P450 2C19 and 2C9 using homology modeling and computational docking.Pharm Res. 2004 Dec;21(12):2270-8. doi: 10.1007/s11095-004-7680-8. Pharm Res. 2004. PMID: 15648259
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources